Investigating The Potential for Immunotherapies in Diffuse Intrinsic Pontine Glioma (DIPG)
DOI:
https://doi.org/10.47611/jsrhs.v11i2.2956Keywords:
Immunotherapies, Diffuse Intrinsic Pontine Glioma, Biomedical Science, CancerAbstract
Cancer is the second leading cause of death worldwide, and has significant economic, social, and emotional effects. Diffuse Intrinsic Pontine Glioma (DIPG), a rare type of cancer, is a devastating pediatric brain tumor that currently has no effective therapy. This disease affects around 150 to 300 children in the United States every year and poses a greater than 98 percent mortality rate within five years of diagnosis. DIPG has been suggested as a potential candidate for immunotherapies and this report’s main focus is on exploring immunotherapies as a treatment for DIPG. It first dives into the impact of cancer on society, introduces DIPG, and explores its biology and prevalence. It then explains the current treatment options, roadblocks, and advantages of immunotherapies over other diseases. This paper concludes by suggesting three most promising immunotherapies for the treatment of DIPG based on their effectiveness in similar brain cancers: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapy.
Downloads
References or Bibliography
World Health Organization. Cancer https://www.who.int/news-room/fact-sheets/detail/cancer.
National Cancer Institute. What Is Cancer? https://www.cancer.gov/about-cancer/understanding/what-is-cancer.
American Cancer Society | Cancer Facts & Statistics http://cancerstatisticscenter.cancer.org/#.
Cancer Facts & Figures 2022| American Cancer Society https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html.
Srikanthan, D.; Taccone, M. S.; Van Ommeren, R.; Ishida, J.; Krumholtz, S. L.; Rutka, J. T. Diffuse Intrinsic Pontine Glioma: Current Insights and Future Directions. Chinese Neurosurgical Journal 2021, 7 (1). https://doi.org/10.1186/s41016-020-00218-w.
Organization, A. C. C. What Is a DIPG Brain Tumor? https://www.acco.org/blog/what-is-a-dipg-brain-tumor/?gclid=CjwKCAiAl-6PBhBCEiwAc2GOVIOhKyFcQK9x44ZBcQhN6iGgPlK2xzvEK6F1zT2IT9DE8Q2HTnb0FBoCUhcQAvD_BwE.
Childhood Diffuse Intrinsic Pontine Glioma - Dana-Farber Cancer Institute | Boston, MA https://www.dana-farber.org/childhood-diffuse-intrinsic-pontine-glioma/.
High Grade Gliomas https://www.cincinnatichildrens.org/health/h/high-grade-gliomas#:%7E:text=High%2Dgrade%20gliomas%20are%20tumors (accessed Mar 21, 2022).
DIPG Statistics https://dipg.org/dipg-stats/(accessed Mar 21, 2022).
DIPG Survival Rate and Prognosis https://dipg.org/dipg-facts/dipg-survival-rate-and-prognosis/ (accessed Mar 21, 2022).
Bernstein, S. DIPG: Rare Brain Tumor in Kids https://www.webmd.com/cancer/brain-cancer/what-is-dipg (accessed Mar 21, 2022).
Kergrohen, T. Copy-number alterations reshape the classification of diffuse intrinsic pontine gliomas. First exome sequencing results of the BIOMEDE trial https://www.medrxiv.org/content/10.1101/2021.04.29.21256183v1.full.
Chromothripsis https://en.wikipedia.org/wiki/Chromothripsis#:~:text=Chromothripsis%20is%20a%20mutational%20process (accessed Mar 21, 2022).
Buczkowicz, P.; Hoeman, C.; Rakopoulos, P.; Pajovic, S.; Letourneau, L.; Dzamba, M.; Morrison, A.; Lewis, P.; Bouffet, E.; Bartels, U.; Zuccaro, J.; Agnihotri, S.; Ryall, S.; Barszczyk, M.; Chornenkyy, Y.; Bourgey, M.; Bourque, G.; Montpetit, A.; Cordero, F.; Castelo-Branco, P. Genomic Analysis of Diffuse Intrinsic Pontine Gliomas Identifies Three Molecular Subgroups and Recurrent Activating ACVR1 Mutations. Nature genetics 2014, 46 (5), 451–456. https://doi.org/10.1038/ng.2936.
Zhang, Y.; Zhang, Z. The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications. Cellular & Molecular Immunology 2020, 1–15. https://doi.org/10.1038/s41423-020-0488-6.
What Is Immunotherapy? | Immunotherapy for Cancer https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy.html#:%7E:text=Immunotherapy%20is%20treatment%20that%20uses (accessed Mar 21, 2022).
Waldman, A. D.; Fritz, J. M.; Lenardo, M. J. A Guide to Cancer Immunotherapy: From T-cell Basic Science to Clinical Practice. Nature Reviews Immunology 2020, 20, 1–18. https://doi.org/10.1038/s41577-020-0306-5.
Immunotherapy (Brain Tumor Vaccine)| Brain Tumor Program | UCI Health | UCI Health | Orange County, CA https://www.ucihealth.org/medical-services/brain-tumor-program/brain-tumor-treatments/immunotherapy-brain-tumor-vaccine (accessed Mar 21, 2022).
McCluskey, K. Immunotherapy vs. Chemotherapy: What’s the Difference? https://www.cancerresearch.org/en-us/blog/june-2016/difference-cancer-immunotherapy-and-chemotherapy.
Reck, M.; Rodríguez-Abreu, D.; Robinson, A. G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; O’Brien, M.; Rao, S.; Hotta, K.; Leiby, M. A.; Lubiniecki, G. M.; Shentu, Y.; Rangwala, R.; Brahmer, J. R. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine 2016, 375 (19), 1823–1833. https://doi.org/10.1056/nejmoa1606774.
Portell, C. How Does CAR T-Cell Therapy Work in Treating Cancer? https://www.cancer.net/blog/2021-06/how-does-car-t-cell-therapy-work-treating-cancer.
Velcheti, V.; Schalper, K. Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book 2016, 36 (36), 298–308. https://doi.org/10.1200/edbk_156572.
Raymond, J. Immunotherapy: How It Works for Cancer https://www.webmd.com/cancer/cancer-how-immunotherapy-works.
Yang, T.; Kong, Z.; Ma, W. PD-1/PD-L1 Immune Checkpoint Inhibitors in Glioblastoma: Clinical Studies, Challenges and Potential. Human Vaccines & Immunotherapeutics 2020, 17 (2), 546–553. https://doi.org/10.1080/21645515.2020.1782692.
Jiang, Y.; Chen, M.; Nie, H.; Yuan, Y. PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Human Vaccines & Immunotherapeutics 2019, 15 (5), 1111–1122. https://doi.org/10.1080/21645515.2019.1571892.
Lei, Q. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors https://www.frontiersin.org/articles/10.3389/fcell.2020.00672/full (accessed Mar 20, 2022).
Shirinbak, S.; Chan, R. Y.; Shahani, S.; Muthugounder, S.; Kennedy, R.; Hung, L. T.; Fernandez, G. E.; Hadjidaniel, M. D.; Moghimi, B.; Sheard, M. A.; Epstein, A. L.; Fabbri, M.; Shimada, H.; Asgharzadeh, S. Combined Immune Checkpoint Blockade Increases CD8+CD28+PD-1+ Effector T-cells and Provides a Therapeutic Strategy for Patients with Neuroblastoma. OncoImmunology 2021, 10 (1). https://doi.org/10.1080/2162402x.2020.1838140.
What are Cancer Vaccines? https://www.cancer.net/navigating-cancer-care/how-cancer-treated/immunotherapy-and-vaccines/what-are-cancer-vaccines.
Cancer Vaccines and Their Side Effects https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/cancer-vaccines.html.
Velcheti, V.; Schalper, K. Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book 2016, 36 (36), 298–308. https://doi.org/10.1200/edbk_156572.
Xu, L. W.; Chow, K. K. H.; Lim, M.; Li, G. Current Vaccine Trials in Glioblastoma: A Review. Journal of Immunology Research 2014, 2014, e796856. https://doi.org/10.1155/2014/796856.
Pollack, I. F.; Jakacki, R. I.; Butterfield, L. H.; Okada, H. Ependymomas: Development of Immunotherapeutic Strategies. Expert Review of Neurotherapeutics 2013, 13 (10), 1089–1098. https://doi.org/10.1586/14737175.2013.840420.
John, P. CAR T-cell Therapy for Pediatric Brain Tumors https://www.frontiersin.org/articles/10.3389/fonc.2020.01582/full (accessed Mar 20, 2022).
Portell, C. How Does CAR T-Cell Therapy Work in Treating Cancer? https://www.cancer.net/blog/2021-06/how-does-car-t-cell-therapy-work-treating-cancer.
Chmielewski, M. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T-cells https://www.frontiersin.org/articles/10.3389/fimmu.2013.00371/full (accessed Mar 20, 2022).
Wang, J. Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma https://www.frontiersin.org/articles/10.3389/fonc.2020.00059/full (accessed Mar 20, 2022).
Choi, B. D.; Maus, M. V.; June, C. H.; Sampson, J. H. Immunotherapy for Glioblastoma: Adoptive T-Cell Strategies. Clinical Cancer Research 2019, 25 (7), 2042–2048. https://doi.org/10.1158/1078-0432.CCR-18-1625.
E.M. Veldhuijzen van Zanten, S. Validate User https://academic.oup.com/neuro-oncology/article/18/4/582/2509342 (accessed Mar 21, 2022).
Three things you need to know about CAR T-cell therapy https://www.cancercenter.com/community/blog/2021/06/car-t-cell-therapy#:%7E:text=CAR%20T%2Dcell%20therapies%20are (accessed Mar 21, 2022).
Holohan, M. Why pediatric cancers receive just 4% of cancer funding https://www.today.com/health/world-cancer-day-2021-why-childhood-cancer-gets-limited-funding-t207903.
Ventola, C. L. Cancer Immunotherapy, Part 3: Challenges and Future Trends. Pharmacy and Therapeutics 2017, 42 (8), 514–521.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Anika Verma; Alexander Wesolowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
